Subscription and usage-based services and software offerings are becoming more common in an industry traditionally dominated by one-time purchases of equipment. Pricing structures are becoming more layered. Trade-ins, rebates, service bundles, and long-term contracts are central to how many deals are structured.  

In our first article, Solving Quote-to-Cash Complexity in Health & Life Sciences and Medtech Manufacturing, we outlined the key trends driving this evolution. Here, we’re going one level deeper—examining what those trends actually mean in practice. 

Identifying trends is the easy part. The real question leaders are now asking is much harder: 

How do we operationalize this complexity without adding headcount, increasing compliance risk, or eroding margins? 

Because inside many organizations today, the commercial engine still looks something like this: 

• Pricing logic buried in spreadsheets 
• Trade-ins and rebates handled manually 
• Sales, service, and finance working across different data sources and processes  
• AI experiments happening outside governed platforms 

Each of these may feel manageable on its own. But together they create friction across the entire revenue lifecycle. Deals slow down. Approvals stall. Pricing becomes inconsistent. And leaders struggle to get a clear picture of what’s actually happening inside their commercial operations. 

This is why many MedTech and Life Sciences organizations are starting to rethink their technology strategy—not by adding more tools, but by addressing the real issue underneath it all. 

Fragmentation. 

Complexity Isn’t the Enemy—Fragmentation Is  

MedTech and Life Sciences companies are inherently complex. That’s not new. 

You’re managing highly regulated products, multi-party contracts, intricate pricing agreements, service commitments, and global compliance requirements. Complexity comes with the territory. 

What creates problems isn’t the complexity itself. It’s the fact that most of it lives in disconnected places. 

Pricing lives in one system. Contracts in another. Service data somewhere else entirely. Finance and ERP data often sit behind yet another layer. The result is a commercial operation where teams spend more time reconciling information than acting on it. 

This is where the platform approach that many organizations are adopting with Salesforce begins to change the equation. Instead of adding point solutions to solve individual problems, companies are bringing core commercial processes into a single environment. 

That allows organizations to: 

• Centralize pricing, contracts, and approvals 
• Apply AI within governed and compliant workflows 
• Connect sales, service, and operations teams around shared data 

When those pieces come together, the conversation shifts. Complexity becomes easier to manage because it’s finally visible and coordinated across the organization. 

AI in Regulated Industries—Without Slowing the Business 

Few topics generate as much excitement—and caution—as AI in MedTech and Life Sciences. 

Leaders see the potential immediately. AI can summarize interactions, surface insights, and help teams make faster decisions.  They can also configure and price quotes on their own – check out a video example of that here. But in regulated industries, there’s a critical question that comes right behind that excitement: 

How do we adopt AI without introducing compliance risk? 

When AI tools operate outside governed systems, several concerns emerge quickly: 

• Exposure of PHI or sensitive customer data 
• Decision-making processes that can’t be audited 
• Uncertainty about how recommendations are generated 

The more effective approach places AI directly inside operational systems where permissions, governance rules, and audit trails already exist. Instead of becoming a separate experiment, AI becomes a natural extension of existing workflows. 

In practical terms, that might mean sales representatives retrieving product eligibility or contract details through conversational interfaces, or AI summarizing customer conversations and generating compliant follow-up actions. Support cases should also be prioritized and routed automatically based on device type, urgency, and service history. 

The goal isn’t simply automation. It’s enabling teams to move faster while still operating within the regulatory guardrails that define the industry. 

Trade-Ins and Rebates: The Hidden Complexity in MedTech Deals 

Trade-ins and rebates are often essential to winning competitive MedTech deals. They help organizations replace aging equipment, compete against rival vendors, and structure deals that work financially for providers. 

But operationally, they can quickly become one of the most complicated parts of the quoting process. 

Eligibility alone can depend on several variables: whether an instrument is owned or leased, the type of competitor equipment involved, existing contractual agreements, and the specific product configuration being proposed. Once those factors are determined, they often trigger pricing adjustments, approval workflows, and new documentation requirements. 

When handled manually, that complexity introduces several risks: 

• Pricing errors that affect deal profitability 
• Approval delays that slow down sales cycles 
• Margin leakage caused by inconsistent discounting 

By bringing trade-in and rebate logic directly into the quoting process, organizations can manage this complexity much more effectively. Sales teams can select trade-in scenarios as part of the quote configuration, while backend rules automatically apply the appropriate discounts, trigger approvals when necessary, and generate the correct documentation. 

The result is a quoting process that remains flexible for complex deals while still protecting pricing integrity and margins. 

Service Operations Are Becoming a Commercial Advantage 

In many MedTech organizations, service teams have a clearer view of customer reality than anyone else. 

They see how devices are actually performing in the field. They know when equipment is failing, when usage is increasing, and when providers are becoming frustrated. Yet historically, much of that information never reaches the sales organization in time to influence commercial decisions. 

Manual case routing and disconnected service systems often make this problem worse. 

When service operations are connected to the broader commercial platform, that dynamic begins to shift. Service cases can be automatically routed based on urgency, device type, and contract terms, ensuring the right technicians are assigned quickly. When those technicians arrive on site, they can access the full asset history, warranty details, and service records associated with the equipment. 

At the same time, service interactions can surface signals that matter commercially. Repeated maintenance issues may point to replacement opportunities. Usage patterns might suggest expansion potential. Aging equipment can indicate when upgrade conversations should begin. 

When those insights flow naturally between service and sales teams, service stops being viewed solely as a support function. It becomes a meaningful contributor to both revenue protection and growth. 

Turning the Installed Base Into a Growth Engine 

Many MedTech executives already recognize that one of their greatest growth opportunities lies within their installed base. Existing customers already trust the technology, rely on it operationally, and maintain ongoing service relationships. 

But unlocking that opportunity requires visibility. 

Data about installed equipment, usage patterns, service activity, and contracts often lives in separate systems that rarely communicate with each other. As a result, organizations miss signals that could indicate expansion, upgrades, or replacement opportunities. 

A unified data environment changes that picture significantly. 

When a customer data platform connects ERP records, service data, contract history, and usage insights, teams can begin identifying opportunities much earlier. Sales teams gain visibility into aging equipment that may soon require replacement. Service teams can highlight customers experiencing rapid growth in device utilization. Commercial teams can bundle equipment upgrades, service plans, and consumables into coordinated offerings that reflect the customer’s real operational needs. 

The installed base stops being a static list of assets and becomes a living source of insight for future growth. 

Pricing Optimization Without the Guesswork 

Pricing in MedTech is rarely straightforward. It’s influenced by GPO and IDN agreements, volume commitments, utilization thresholds, regional market pressures, and global governance policies. 

Because of that complexity, many pricing teams spend most of their time reacting to deals rather than shaping them. 

Without centralized visibility, it’s difficult to know whether a deal aligns with margin targets or whether similar customers are receiving drastically different pricing. Approvals slow down as teams manually validate discount structures and contract terms. 

When pricing data and rules are consolidated within a single environment, the dynamic changes. Organizations can analyze deal health in real time, enforce pricing guardrails automatically, and streamline approvals for exceptions when they occur. 

Instead of constantly asking whether the right price was used, teams gain confidence that pricing policies are being applied consistently across the organization. 

The Bigger Picture 

For MedTech and Life Sciences organizations exploring this shift, it helps to think about the commercial platform in simple terms. 

At its core, it brings together four essential capabilities: 

• Revenue management for pricing, quoting, contracts, and rebates 
• AI embedded directly into operational workflows 
• A unified data layer connecting ERP, service, and commercial systems 
• Field service capabilities that manage the installed base in real time 

Together, these elements create a single commercial backbone rather than a collection of disconnected tools. 

And that’s where the real transformation happens. 

Because as MedTech and Life Sciences organizations continue to evolve their business models, one thing is becoming increasingly clear: 

The challenge isn’t complexity.  It’s whether your systems are equipped to manage it. 

With over two decades of experience delivering complex Q2C solutions, Pierce Washington understands the unique challenges that health and life sciences manufacturers face. From global leaders like Thermo Fisher, McKesson, and Fujifilm Health, the focus has remained the same: aligning process, technology, and data to drive measurable outcomes. 

Bringing these capabilities onto a unified commercial platform doesn’t just simplify operations—it accelerates deal cycles, improves pricing consistency, reduces compliance risk, and gives leaders real-time visibility across the revenue lifecycle. 

If you’re evaluating how to modernize your quote-to-cash strategy, Pierce Washington can help. Talk to our team to get a clear, practical assessment of where you are today—and what it will take to get you where you need to be.